We have scheduled our third TDOL for July 27th, 2024 at 10-2:30pm MT in Aurora, CO at UC Health Anschutz Cancer Center!
A TDOL is a free half day event to help TGCT patients and caregivers learn more about this rare disease, find support, and enhance their knowledge base to help them navigate their journey.
TGCT Support has a simple purpose: to improve treatment of a rare disease — TGCT — and to help those living with it. To do this, TGCT Support focuses on three key areas: research, patient support & education, and advocacy, which lay the foundation of our mission to ensure the quality of life of TGCT patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of TGCT advocates and the global health and research environment. During this conference, Dr Stern will cover background biology and history of the disease, Dr Breelyn Wilky will cover medications and clinical trials, and Dr Nathan Donaldson will cover Pre-Operative Treatment and Surgical Management of the disease. Lastly, we will have a roundtable discussion with experts. Lunch is included and the event is FREE to anyone who wants to meet and learn.
Thank you to our sponsors, Daiichi Sankyo, Deciphera, Biologics, and SynOx.
TGCT Support is collaborating with SPAGN to host a TGCT Day of Learning Conference on April 20th, 2024 at the Precise House Mantegna Roma (Vía Andrea Mantegna, 130 00147, Rome, Italy)!
The event is free to patients and their family.
For any questions, email SStern@TGCTSupport.org
Stay tuned for the recording!
TGCT Day of Learning (TDOL) AT OSU
We have scheduled our second TDOL for Sept 23rd, 2023 at 10-2:20pm ET in Columbus, Ohio at OSU!
A TDOL is a free half day event to help TGCT patients and caregivers learn more about this rare disease, find support, and enhance their knowledge base to help them navigate their journey.
TGCT Support has a simple purpose: to improve treatment of a rare disease — TGCT — and to help those living with it. To do this, TGCT Support focuses on three key areas: research, patient support & education, and advocacy, which lay the foundation of our mission to ensure the quality of life of TGCT patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of TGCT advocates and the global health and research environment. During this conference, Dr Stern will cover background biology and history of the disease, Dr Burgess from UPMC will cover Imatinib and the Turalio trials, Dr Tinoco from OSU will cover the trial therapies, and Dr Scharschmidt from Children's National Hospital will cover Pre-Operative Treatment and Surgical Management of the disease. Lunch is included and the event is FREE to anyone who wants to meet and learn.
Thank you to our sponsors, Abbisko, Daiichi Sankyo, and Deciphera, that made it possible
Our first ever TGCT Days of Learning (TDOL) conference was on Sept 21st, 2022 from 4-8pm in NYC.
A TDOL is a free half day event to help TGCT patients and caregivers learn more about this rare disease, find support, and enhance their knowledge base to help them navigate their journey.
TGCT Support has a simple purpose: to improve treatment of a rare disease — TGCT — and to help those living with it. To do this, TGCT Support focuses on three key areas: research, patient support & education, and advocacy, which lay the foundation of our mission to ensure the quality of life of TGCT patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of TGCT advocates and the global health and research environment. During this conference, Dr Stern will cover background biology and history of the disease, Dr Schwartz from Columbia Presbyterian Hospital will cover systemic therapies and clinical trials, and Dr Prince and Healey from MSKCC will cover Pre-Operative Treatment and Surgical Management of the disease. Dinner is included and the event is FREE to anyone who wants to meet and learn.
For those that cannot come, do not worry! This will be the first of many.
Thank you to our sponsors, Daiichi Sankyo, SynOx Therapeutics and Deciphera, that made it possible